FDA Panel Backs Allergan's Drug For Frequent Nightly Urination
The benefits associated with Allergan Plc's experimental drug to treat frequent nightly urination outweigh the risks for certain patients, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.
The panel voted 14-4 to recommend that the drug, SER120, be approved for certain patients with nocturia, defined as waking to urinate two or more times a night.
The FDA is not obliged to follow its advisory panel's recommendations, but typically does so.
The panel voted 14-4 to recommend that the drug, SER120, be approved for certain patients with nocturia, defined as waking to urinate two or more times a night.
The FDA is not obliged to follow its advisory panel's recommendations, but typically does so.